iv fluid monitoring devices market

Contakt World Provides Company Update as it Continues to Expand its Portfolio of SaaS Solutions and Commercial Presence in the US Market

Contakt World is well-positioned to continue to take a leading role as a provider of SaaS solutions designed to meet Federal Vaccine Mandates imposed by the United States

  • A vaccine mandate was recently enacted in the United States for all Federal employees
  • The private sector is following suit, creating demand for Contakt World's portfolio
  • Health Check and Portum's app offers the public and private sector a unique, integrated solution

Contakt World Technologies Corp. (CSE: HELP) (OTC Pink: TLOOF) (FSE: B2I0) (the "Company", "Contakt" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges such as symptom screening and vaccine passports, is pleased to provide a summary of the Company's recent achievements, current operations, and strategic initiatives.

Contakt World has ambitious plans to advance its business following its acquisition of Stratum Health Solutions LLC ("Stratum"), the operator of HealthCheck by Stratumâ„¢ ("HealthCheck") and execution of a reseller's agreement with Portum System LLC ("Portum") for the US, Canada, and Brazil markets. A review of the Company's recent achievements and current business is as follows:

  • On August 12, 2021, Contakt acquired Stratum (Health Check) a secure, cloud-based platform that allows organizations of all sizes to track and evaluate employee and student health and COVID-19 related symptoms in real-time through its proprietary app (the "App"). Contakt continues to expand its presence in the marketplace with Health Check with the hiring of 10 commission-based sales people over the last few months. The Company's team is fully trained and has acquired 20+ significant new customers over the last few months with over 25 new commercial opportunities in the pipeline. Contakt has engaged a software development company, ModalGR, located in Brazil, to add new features to the App, including vaccine passport and COVID-19 test tracking. Contakt expects to launch the new version of the App in December of this year.
  • On October 14, 2021, Contakt expanded its commercial portfolio through a partnership agreement with Portum through which the Company will offer Portum's app and software to commercial and government customers to help implement vaccine mandates in public and private settings. The Company's sales team has been fully trained and has started to promote this SaaS product across the USA. This solution will allow the Company to immediately offer a vaccine passport and COVID-19 test tracking solution to its existing and new customers. With several states, such as New York and California, enforcing vaccine mandates, Contakt is focusing on these territories to rapidly gain market share.
  • Contakt recently hired Alexandre Kochmann, a seasoned executive located in Brazil, to oversee the commercialization and product development of the Health Check and Portum solutions. Alexandre brings 20+ of experience managing large commercial sales forces at large corporations such as Dupont, GLOBALPACK and EMPAX.
  • With a focus on the private sector, Contakt has dramatically reduced its burn rate. While the Company sees long-term opportunities in the public health markets, it is focusing on continuing to build the Health Check business and partnership with Portum.
  • Contakt is also eyeing opportunities in the Brazilian market and anticipates having a Portuguese version of the App ready in the first half of 2022, which will allow it to offer a robust solution to one of the largest economies in the world.

"By leveraging the Company's expanding team of independent sales representatives and continuing the development of our Health Check platform to meet the needs of vaccine passport and COVID-19 test tracking mandates, we believe our team will serve as a strong platform to develop and acquire additional SaaS solutions, ultimately strengthening our product portfolio," stated Zayn Kalyan, Chief Executive Officer of Contakt World.

Corporate Update Webinar
Contakt will be hosting a corporate update webinar for shareholders at 12pm PST on Friday November 19, 2021. Please click here to register.

Other Recent Related News from Contakt World:

Contakt World Launches Sales Representative Program to Continue to Grow Revenue for Its Cash Flow Positive HealthCheck Screening Tool and Vaccine Passport Solution

Contakt World to Offer Vaccine Passport and Verification Platform to Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

Contakt World Announces Acquisition of HealthCheck, a SaaS Health Screening App for Students, Customers, Employees, and Visitors

To Learn More:
If you are an organization seeking daily health screening and vaccine passports, vaccine wallets, or vaccine credentials, schedule a demo by visiting https://www.stratumhealth.io/. Our team will work with your organization to define the product that better suits your needs.

About Contakt World
Contakt World's mission is to develop or acquire and deliver software (SaaS) that improves access to, efficiencies within, and quality of healthcare in all its forms. Contakt World envisions a world where everyone can achieve their full health potential, and no one is disadvantaged from achieving this potential because of social position or other circumstances. Contakt World's portfolio presently includes HealthCheck by Stratum which is used in over 1,000 locations, and Portum Pass https://contakt.world/portum/.

Sign up for investor updates from Contakt World including updates in the field of vaccine passports by visiting https://contakt.world/help.

Contakt World Contact
Zayn Kalyan
Interim CEO and Director
Direct: 778-938-3367

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Forward-Looking Statements Disclaimer

This press release contains "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "projects", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements, including statements respecting: the Company's plans to advance its business following its acquisition of Stratum and partnership agreement with Portum; Contakt's plan to launch a new version of the App in December 2021; the Portum arrangement's potential to allow the Company to immediately offer a vaccine passport and COVID-19 test tracking solution to its existing and new customers; the Company's focus on continuing to build the Health Check business and partnership with Portum; expected timing and functionality of a Portuguese version of the App; the Company's belief that its team will serve as a strong platform to develop and acquire additional SaaS solutions, ultimately strengthening the Company's product portfolio. Although forward-looking statements contained in this press release are based upon what management of Contakt World believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. Contakt World undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103682

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy ("THT") treatment shrunk within the first 24 hours, with an average reduction in size of 80% compared to matched controls.

Study Principal Investigator, Dr. Carman Giacomantonio, comments, "Our initial assessment documented that in cohorts of seven animals, 7/7 of treated triple negative breast cancer mouse tumors bearing gold nanorods responded with an average reduction in tumor volume of 80% following a single treatment with near infrared light in comparison with untreated 'control' tumors. Interestingly, in all cases we observed responses (tumor shrinkage) in distant, untreated tumors supporting the hypothesis that our observations are consistent with systemic immunogenic responses. This observation will be a significant focus of our research going forward. While we are encouraged by these initial results, there is still significant work to be completed. The studies are designed to enable and identify statistical significance which will be achieved with the completion of the full Study."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ARway.ai Announces Major 300,000 SQ FT or 30,000 M. Retail Store Pilot of its AR Navigation Platform

ARway.ai Announces Major 300,000 SQ FT or 30,000 M. Retail Store Pilot of its AR Navigation Platform

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce its new partnership with Megatek Albania's leading home improvement and do-it-yourself (DIY) retailer. This groundbreaking collaboration is set to bring an unprecedented retail experience to the Albanian market, beginning with a pilot program at Megatek's expansive flagship store that spans more than 323,000 square feet

The successful implementation of ARway's technology in Megatek's flagship store will pave the way for future deployments across more locations and similar stores, signaling a significant growth and revenue opportunity for both companies.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
NEO Battery Materials Announces Change of Auditor to MNP LLP

NEO Battery Materials Announces Change of Auditor to MNP LLP

NEO Battery Materials Ltd. (" NEO " or the " C o mpan y ") ( T S X V : NBM ) ( OTC: NBMFF ), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that it has changed its auditors from DeVisser Gray LLP (" Former Auditor ") to MNP LLP (" Successor Auditor "), effective March 19, 2024.

NEO Battery's board of directors accepted the resignation of DeVisser Gray LLP and appointed MNP LLP as the new auditor of the Company, effective March 19, 2024, until the Company's next annual general meeting of shareholders.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NANALYSIS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND CONCURRENT PRIVATE PLACEMENT

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./

Nanalysis Scientific Corp. (TSXV: NSCI) (the " Company " or " Nanalysis ") is pleased to announce that it has closed its prospectus exempt offering of units (the " Offering ") and concurrent brokered "best efforts" prospectus exempt offering of units (the " Concurrent Offering" ), as announced on March 6, 2024 . A total of 11,111,110 units (the " Units ") were issued at a price of $0.45 per Unit for gross proceeds of $4,999,999.50 . A total of 8,888,888 Units were issued pursuant to the Offering and 2,222,222 Units were issued pursuant to the Concurrent Offering.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
ARway.ai Announces EWROS as New Partner in Turkey for its Augmented Reality Navigation Experience Platform

ARway.ai Announces EWROS as New Partner in Turkey for its Augmented Reality Navigation Experience Platform

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce a paid partner deal with EWROS, a leading developer of automation systems software based out of Turkey. This new partner is another step in ARway.ai's expansion, aligning with EWROS's recognized position in the region as a premier automation solutions provider

EWROS becomes an integral part of the ARway ecosystem, licensing ARway's innovative platform for large-scale projects within the region. This partnership allows EWROS to leverage ARway's cutting-edge AR technology in conjunction with their existing IoT deployments, thereby offering a comprehensive tech stack to their clientele.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Sona Nanotech Announces Filing of Provisional Patent Application

Sona Nanotech Announces Filing of Provisional Patent Application

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, "ENDOSCOPE WITH EMR OPTICAL FIBER AND THERMAL SENSOR FOR PHOTOTHERMAL THERAPY".

A prototype of Sona's medical laser was engineered in conjunction with Minnetronix Medical to apply non-thermal, 860 nanometer wavelength high intensity infrared laser light. The device has been designed for use with Sona's patented/patent pending biocompatible gold nanorods which efficiently convert the non-thermal light energy into heat. The device has controls to regulate the intensity and duration of the light exposure and to permit a user to monitor and control the temperature generated in tissue. The device is currently being used for the Company's ongoing pre-clinical efficacy study of its Targeted Hyperthermia Therapy cancer treatment at Dalhousie University.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×